These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 37463858)

  • 1. Using artificial intelligence to learn optimal regimen plan for Alzheimer's disease.
    Bhattarai K; Rajaganapathy S; Das T; Kim Y; Chen Y; ; ; Dai Q; Li X; Jiang X; Zong N
    J Am Med Inform Assoc; 2023 Sep; 30(10):1645-1656. PubMed ID: 37463858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Artificial Intelligence to Learn Optimal Regimen Plan for Alzheimer's Disease.
    Bhattarai K; Das T; Kim Y; Chen Y; Dai Q; Li X; Jiang X; Zong N
    medRxiv; 2023 Jan; ():. PubMed ID: 36747733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
    Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
    CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
    Schneider LS; Insel PS; Weiner MW;
    Arch Neurol; 2011 Jan; 68(1):58-66. PubMed ID: 21220675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.
    Lampela P; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
    J Alzheimers Dis; 2020; 73(3):1243-1251. PubMed ID: 31929157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
    Schneider LS; Dagerman KS; Higgins JP; McShane R
    Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
    Zhu CW; Livote EE; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
    Alzheimers Dement; 2013 Nov; 9(6):733-40. PubMed ID: 23332671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
    Zhang N; Wei C; Du H; Shi FD; Cheng Y
    Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
    Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
    J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort.
    Bloudek LM; Spackman DE; Veenstra DL; Sullivan SD
    J Alzheimers Dis; 2011; 24(3):599-607. PubMed ID: 21297268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
    Mielke MM; Leoutsakos JM; Corcoran CD; Green RC; Norton MC; Welsh-Bohmer KA; Tschanz JT; Lyketsos CG
    Alzheimers Dement; 2012 May; 8(3):180-7. PubMed ID: 22301194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug treatment of Alzheimer's dementia : Status quo and perspectives].
    Müller P; Fendt M; Müller NG
    Internist (Berl); 2019 Jul; 60(7):761-768. PubMed ID: 31139854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
    Liang J; Li J; Jia R; Wang Y; Wu R; Zhang H; Hang L; Xu Y
    Clin Interv Aging; 2018; 13():2061-2073. PubMed ID: 30425461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.